Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma

Haematologica. 2015 Nov;100(11):e450-3. doi: 10.3324/haematol.2015.132837. Epub 2015 Aug 20.
No abstract available

Keywords: CTCL; JAK mutations; JAK/STAT; molecular diagnostics; ruxolitinib; targeted therapy.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Janus Kinases / genetics*
  • Janus Kinases / metabolism*
  • Lymphoma, T-Cell, Cutaneous* / drug therapy
  • Lymphoma, T-Cell, Cutaneous* / genetics
  • Lymphoma, T-Cell, Cutaneous* / metabolism
  • Male
  • Middle Aged
  • STAT Transcription Factors / genetics
  • STAT Transcription Factors / metabolism*
  • Signal Transduction / drug effects*
  • Signal Transduction / genetics*

Substances

  • STAT Transcription Factors
  • Janus Kinases